Please assess the completion status of the following clinical trial:

Trial Title: French Evaluation Group Avastin Versus Lucentis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50 years old~* Affected by neovascular retrofoveal AMD whatever the subtype, unilateral or bilateral (the eye included will be chosen by the investigator and the patient);~* Best corrected VA for the studied eye ranging between 20/32 (6.3/10) and 20/320 (0.6/10) with ETDRS scale~* Size of lesion \< 12 disk area~* In case of occult neovessels, proof required of recent development of the lesion: loss of VA of at least 5 letters ETDRS (equivalent one line) in the last 3 months OR appearance of a subretinal heamorrhage OR increase in the size of the lesion (\> 10%) using fluoresceinic angiography during the last month by comparison with the last 3 months OR appearance of OCT criteria of macular oedema type, serous separation of neuro-epithelium, separation of the pigmented epithelial during the last month~* Effective birth control for sexually active female~* Signed informed consent.~Exclusion Criteria:~* Previous or actual treatment with intravitreal injection of an anti-VEGF drug (ranibizumab, bevacizumab or pegaptanib) in the studied eye~* Other healing treatment in the studied eye during the last 3 months before the first injection~* Medical history of photocoagulation in the studied eye~* Involvement in another clinical study (studied eye and/or the other eye)~* Subretinal haemorrhage reaching the fovea centre, with a size \> 50% of the lesion area~* Fibrosis or retrofoveal retinal atrophy in the studied eye~* Retinal pigment epithelial tear reaching the macula in the studied eye~* Choroidal neovascularisation not related to a DMLA in the studied eye~* Medical history of intravitreal medical device in the studied eye~* Active or suspected ocular or peri-ocular infection~* Serious active intra-ocular inflammation in the studied eye~* Medical history of auto-immune or idiopathic uveitis~* Proved diabetic retinopathy~* Intra-ocular pressure ≥ 25 mmHg despite two topical hypotonic treatments~* Medical history of intra-ocular surgery within 2 months before the first injection in the studied eye~* Aphakia or lack of lens capsule (not removed by YAG laser) in the studied eye~* Any illness or ocular condition that would require an intra-ocular surgery in the studied eye within 12 months after the inclusion~* Known hypersensitivity to ranibizumab, bevacizumab, or another drug composite of the medicinal products used; allergy to fluorescein, indocyanin green, anaesthetic eye drops~* Arterial hypertension that is not controlled by an appropriate treatment~* Previous or actual treatment with systemic administration of bevacizumab~* Follow up not possible during 12 months~* No affiliation to the French national health insurance program.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin (Type: EXPERIMENTAL): intravitreal injection of bevacizumab
- Lucentis (Type: ACTIVE_COMPARATOR): intravitreal injection of ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).